Primary Care Perspectives: Episode 154 - Nirsevimab (Beyfortus)

For the first time, a preventative medicine is available to protect infants and high-risk toddlers from respiratory syncytial virus (RSV). Lori Handy, MD, MSCE, attending physician in the Division of Infectious Diseases at Children's Hospital of Philadelphia, details the science behind the monoclonal antibody, nirsevimab (Beyfortus) and its importance, safety and efficacy, side effects, administration and proven benefits, such as a decrease in morbidity, as shown by clinical trials; and more. This podcast is for general informational and educational purposes only and is not to be considered as medical advice for any particular patient. Clinicians must rely on their own informed clinical judgment in making recommendations to their patients. ©2023 by Children's Hospital of Philadelphia, all rights reserved.